A promising start for checkpoint inhibitors in childhood malignancies.,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A promising start for checkpoint inhibitors in childhood malignancies.
The Lancet Oncology ( IF 41.6 ) Pub Date : 2019-12-04 , DOI: 10.1016/s1470-2045(19)30803-4
Hussein Tawbi ₁

Affiliation

Therapeutic advancements in childhood malignancies are a particularly difficult challenge, with these malignancies consistently under-represented in early-phase clinical trials of novel anticancer therapies. Although a majority of childhood malignancies are curable, they require highly aggressive and intense therapy that leaves patients with potentially detrimental long-term side-effects. Therefore, the identification of treatment approaches that are more effective and ideally less toxic remains an urgent need.

中文翻译：

儿童恶性肿瘤中检查点抑制剂的有希望的开端。

儿童恶性肿瘤的治疗进展是一个特别困难的挑战，在新的抗癌治疗的早期临床试验中，这些恶性肿瘤的代表性一直不足。尽管大多数儿童恶性肿瘤是可以治愈的，但它们需要高度积极和激烈的治疗，这会使患者长期遭受潜在的不利影响。因此，鉴定更有效且理想地毒性较小的治疗方法仍然是迫切需要。

更新日期：2020-01-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文